Future oncology最新文献

{"title":"Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary.","authors":"Claire N Harrison, Sonia Fox, Rebecca Boucher, Mary Frances McMullin, Adam J Mead","doi":"10.1080/14796694.2024.2406597","DOIUrl":"10.1080/14796694.2024.2406597","url":null,"abstract":"<p><p>[Figure: see text].</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3365-3376"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142345007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory markers correlate with lymphocytes infiltrating and predict immunotherapy prognosis for esophageal cancer.","authors":"Bei Wang, Zixuan Wang, Kun Wang, Zhongming Shao, Haitao Chen, Lincheng Xu, Yan Pan, Mingyue Zheng, Wei Geng, Chuanhai Xu","doi":"10.1080/14796694.2024.2421151","DOIUrl":"10.1080/14796694.2024.2421151","url":null,"abstract":"<p><p><b>Aim:</b> To investigate the prognostic value of inflammatory markers in esophageal squamous cell carcinoma (ESCC) patients treated with immune checkpoint inhibitors (ICIs).<b>Materials & methods:</b> The infiltration of CD3⁺ and CD8⁺ T cells in tissue microarrays from 180 patients who underwent radical esophagectomy was detected using immunohistochemistry. A separate cohort of 351 patients with metastatic/recurrent or unresectable ESCC treated with ICIs was enrolled for further investigation. The overall survival difference among groups was assessed using Kaplan-Meier analysis. Cox proportional hazards models were employed to investigate the prognostic impact of the inflammatory markers, along with other factors.<b>Results:</b> Decreased inflammation was found to be associated with increased CD3⁺ and CD8⁺ T-cell infiltration and a better prognosis. Then, the value of inflammatory markers in predicting survival in 351 ESCC patients receiving immunotherapy was validated. Ultimately, the systemic immune-inflammation index was identified as an independent prognostic factor for overall survival. Additionally, the patients with no distant organ metastasis, or treated by first-line immunotherapy combined with concurrent chemoradiotherapy can considerably prolong survival.<b>Conclusion:</b> Inflammation is associated with the level of tumor infiltrating lymphocytes and that the systemic immune-inflammation index is an effective prognostic predictor for ESCC patients treated with ICIs.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3267-3278"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic syndrome and symptom burden in allogeneic hematopoietic stem cell transplantation survivors.","authors":"Jonathan Q Trinh, Jonathan D Nilles, Moataz Ellithi, Michael M Haddadin, Lori Maness-Harris, Krishna Gundabolu, Christopher S Wichman, Vijaya R Bhatt","doi":"10.1080/14796694.2024.2431476","DOIUrl":"10.1080/14796694.2024.2431476","url":null,"abstract":"<p><strong>Introduction: </strong>Allogeneic hematopoietic stem cell transplantation (HCT) improves survival of patients with hematologic malignancies. A growing responsibility exists to identify and address long-term morbidity and symptom burden. We investigated metabolic syndrome and symptom burden in adult HCT survivors.</p><p><strong>Methods: </strong>We analzyed adults with hematologic disorders who were treated with allogeneic HCT at our institution from June 2018-November 2022. We used standard criteria for metabolic syndrome with body mass index (BMI) as a surrogate for waist circumference. We assessed symptom burden using the National Comprehensive Cancer Network Survivorship Assessment. The Short Physical Performance Battery and Short Blessed Test were used to investigate physical function and cognition, respectively.</p><p><strong>Results: </strong>A total of 152 patients were included. Median age was 61 years, 59% were male, and the most common disorder was acute myeloid leukemia (48%). 64 patients developed metabolic syndrome post-transplant. The most commonly affected symptom domains were fatigue (51%), sleep (45%), and cognitive function (42%). Additionally, 34% and 7% of patients had objectively impaired functional capacity and cognition, respectively.</p><p><strong>Conclusion: </strong>Recipients of allogeneic HCT have a high incidence of metabolic syndrome, symptom burden, and impaired physical function.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3403-3408"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of dual bronchodilators plus preoperative rehabilitation in operable LC & chronic obstructive pulmonary disease.","authors":"Rong Zhou, Yan Qin, Song Hu, Yangyang Xu, Chunlai Feng","doi":"10.1080/14796694.2024.2430164","DOIUrl":"10.1080/14796694.2024.2430164","url":null,"abstract":"<p><strong>Background: </strong>This study analyzed the application of dual bronchodilators in patients with non-small cell lung cancer (NSCLC) & chronic obstructive pulmonary disease (COPD) during the perioperative period.</p><p><strong>Research design and methods: </strong>A total of 100 patients with moderate to severe COPD who underwent thoracoscopic lobectomy were divided into two groups. The patients in the observation group (group O) were treated with umeclidinium/vilanterol and conventional treatment (oxygen therapy, assisted expectoration, respiratory rehabilitation training) during the perioperative period. The patients in the control group (group C) received conventional treatment. Lung function, arterial blood gas values, quality of life, postoperative adverse reactions, days of postoperative chest tube placement and hospitalization were assessed.</p><p><strong>Results: </strong>Before surgery, group O presented higher FEV1, FVC, PEF and MVV, elevated PO₂ and reduced PCO₂, lower CAT scores compared with the group C (<i>p</i> < 0.05). The group O demonstrated fewer perioperative adverse reactions, and shorter days of postoperative chest tube and hospitalization compared with the group C (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Perioperative inhalation of umeclidinium/vilanterol can effectively protect arterial blood gas and respiratory function in patients with LC complicated with COPD.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3471-3476"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer.","authors":"Neal D Shore, Michael S Cookson, Eleni Efstathiou","doi":"10.1080/14796694.2024.2418801","DOIUrl":"10.1080/14796694.2024.2418801","url":null,"abstract":"<p><p>In this podcast discussion, we review the landscape of androgen deprivation therapies (ADT) for the treatment of advanced prostate cancer. Prior to 2020, available ADT options to achieve chemical castration included gonadotropin-releasing hormone receptor agonists (e.g., leuprolide) and antagonists (e.g., degarelix) administered via muscular or subcutaneous injection. In 2020, the once-daily oral gonadotropin-releasing hormone antagonist, relugolix, received US regulatory approval for the treatment of advanced prostate cancer based on results from the Phase III HERO trial. In this podcast, we also discuss the primary efficacy and safety results of this trial, and key points for providers and patients to consider as they discuss the different ADT options.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3351-3354"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tislelizumab for consolidation therapy in patients with pathologically residual Esophageal Squamous Cell Carcinoma after definitive concurrent Chemoradiotherapy: a multicenter, randomized, controlled phase II trial.","authors":"Xi Meng, Hongfu Sun, Tiantian Cui, Wei Huang","doi":"10.1080/14796694.2024.2432290","DOIUrl":"10.1080/14796694.2024.2432290","url":null,"abstract":"<p><p>Although concurrent Chemoradiotherapy (cCRT) is presently the standard intervention for patients with inoperable, locally advanced Esophageal Squamous Cell Carcinoma (ESCC), it has been associated with poor long-term survival outcomes. Notably, Immune Checkpoint Inhibitors (ICIs) improve the long-term survival of Esophageal Cancer (EC) patients, with manageable Adverse Effects (AEs). Herein, 90 patients with residual pathology after radical simultaneous Radiotherapy (RT) for inoperable/refused-to-operate ESCC were enrolled and randomized into two treatment groups (Chemotherapy+immunotherapy and chemotherapy alone) in a 2:1 ratio. This study will also discuss the value of immunotherapy in improving long-term survival outcomes in patients with pathological residuals after concurrent RT for locally advanced, inoperable ESCC.Clinical trial registration: http://www.chictr.org.cn/identifier is ChiCTR2200063345.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3397-3402"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142727243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.","authors":"Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, Tony S K Mok, Ross A Soo, Julien Mazieres, Alice T Shaw, Filippo de Marinis, Yasushi Goto, Yi-Long Wu, Dong-Wan Kim, Jean-François Martini, Rossella Messina, Jolanda Paolini, Anna Polli, Despina Thomaidou, Francesca Toffalorio, Todd M Bauer","doi":"10.1080/14796694.2024.2406117","DOIUrl":"10.1080/14796694.2024.2406117","url":null,"abstract":"<p><strong>What is this study about?: </strong>This is a summary of the results of an ongoing study called CROWN. In the CROWN study, researchers looked at the effects of two medicines called lorlatinib (Lorbrena) and crizotinib (Xalkori) for people with advanced non-small cell lung cancer (NSCLC) who had not been treated yet. Everyone in the study had changes in a <b>gene</b> called anaplastic lymphoma kinase, or <i>ALK</i>, in their cancer cells. The changes in the <i>ALK</i> gene can make cancer grow. This analysis looked at how well lorlatinib and crizotinib worked and their <b>side effects</b> in people with advanced <i>ALK</i>-positive NSCLC after 5 years.</p><p><strong>What did this study find?: </strong>After observing people for an average of 5 years, researchers found that more people who took lorlatinib were still alive without their cancer getting worse than the people who took crizotinib. At 5 years, the probability of being alive without their cancer getting worse was 60% in people who took lorlatinib compared with 8% in people who took crizotinib. Fewer people who took lorlatinib had their cancer spread within or to the brain than the people who took crizotinib. In more than half of the people who took lorlatinib, tumors that had spread to the brain did not get worse, and no new tumors spread to the brain after 5 years. In contrast, in about half of the people who took crizotinib, tumors that had spread to the brain got worse or new tumors spread to the brain after 16.4 months. More people who took lorlatinib (115 out of 149, or 77%) had <b>severe</b> or <b>life-threatening side effects</b> than people who took crizotinib (81 out of 142, or 57%). These side effects were like the ones reported in the earlier 3-year analysis.</p><p><strong>What do the findings of the study mean?: </strong>The 5-year results from the CROWN study showed that more people who took lorlatinib continued to benefit from their treatment than those who took crizotinib. The 5-year benefit of lorlatinib in people with <i>ALK</i>-positive NSCLC has never been seen before.<b>Clinical Trial Registration:</b> NCT03052608 (Phase 3 CROWN study) (ClinicalTrials.gov).</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3377-3387"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the effects of exercise protocols in hospitalized onco-hematological patients: a systematic review.","authors":"Bruna Cunha de Souza, Cintia Freire Carniel, Rodrigo Daminello Raimundo","doi":"10.1080/14796694.2024.2429942","DOIUrl":"10.1080/14796694.2024.2429942","url":null,"abstract":"<p><strong>Introduction: </strong>Physical activity is associated with improved functionality, independence and quality of life in cancer patients undergoing active treatment. Exercises can be prescribed to improve patient outcomes.</p><p><strong>Objective: </strong>Evaluate the effects of applied exercise protocols on functional capacity, quality of life, fatigue and muscle strength in hospitalized onco-hematological patients compared to conventional treatment.</p><p><strong>Method: </strong>Systematic literature review carried out in PUBMED, EMBASE and Scopus databases with the following descriptors: <i>Hematological neoplasms AND Exercise Therapy AND Hospitalization</i>, in November 2023. Studies with adult inpatients with hematological neoplasms who performed an exercise protocol in the intervention group were included.</p><p><strong>Results: </strong>After applying the eligibility criteria, 9 articles were included in the review, 7 of which were randomized clinical trials and 6 were carried out on transplant patients. The most commonly assessed outcome was functional capacity, followed by muscle strength and quality of life, and ending with an assessment of fatigue. Studies have shown positive results for patients, especially those that combine resistance and aerobic exercise protocols.</p><p><strong>Conclusion: </strong>An exercise protocol for patients with onco-hematological diseases can improve the outcomes analyzed. Aerobic and resistance exercises should be performed, but more studies are needed to assess the time and doses required for each activity.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3301-3312"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The pivotal role of autophagy in the pathogenesis and therapy of medulloblastoma.","authors":"Seidu A Richard","doi":"10.1080/14796694.2024.2420629","DOIUrl":"10.1080/14796694.2024.2420629","url":null,"abstract":"<p><p>Medulloblastoma (MB) is the most frequent malignant brain tumor in children. MB originates from neural precursor cells in distinctive regions of the rhombic lip and their maturation occurs in the cerebellum or the brain stem during embryonal development. Autophagy is also referred to as self-eating' which is a catabolic process that often triggers cellular homeostasis through the salvaging of degenerated proteins as well as organelles. Autophagy influence cell survival via aberrant proteins that could accumulate within the cell and influence potential signaling and transport mechanisms. The role of autophagy in MB aggressiveness as well as tumorigenesis is a very complex process. This review targets specifically data reporting the key roles of autophagy in the pathogenesis and therapy of MB.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3313-3324"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Part 2 - Highlights of the San Antonio Breast Cancer Symposium 2023.","authors":"John R Benson, Ismail Jatoi","doi":"10.1080/14796694.2024.2418797","DOIUrl":"10.1080/14796694.2024.2418797","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3347-3350"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}